AzTrials
AzTrials

Diabete Type 2LELOHGNCT07108426

Medical Education to Improve Diabetes Care and Outcomes in Hospitalized Patients

A study testing Educational Intervention via Telemedicine in people with Diabete Type 2 and Hyperglycemic Therapy, run by Catholic University of Pelotas at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This clinical trial aims to evaluate whether a structured medical education strategy can improve the quality of care provided to hospitalized patients with diabetes or hyperglycemia. Read more about this study

Who is it for?
Ages 20 years and older
What is being tested?
Educational Intervention via Telemedicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteBrazil
Study dates
1 Aug 2024to 31 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Internal medicine residents from clinical teams at the participating university hospitals in southern Brazil.
  • Residents assigned to clinical teams during the intervention month.
  • Provided informed consent to participate in the study.

Who cannot join

  • Residents on vacation during the intervention month.
  • Residents from teams supervised by endocrinologists.
  • Refusal to participate in the study.

Trial locations and contacts

1 site in 1 country.

Brazil1 site

  • Catholic University of Pelotas

    Pelotas, Rio Grande do Sul, 96075160

Other trials in Brazil

About this study

Official title: Evaluation of the Impact of In-Person and Telemedicine-Based Medical Education on Diabetes Care and Outcomes in Hospitalized Patients

This clinical trial aims to evaluate whether a structured medical education strategy can improve the quality of care provided to hospitalized patients with diabetes or hyperglycemia. Internal medicine residents from four university hospitals in southern Brazil are assigned to two groups: an intervention group receiving a 30-minute online lecture and 30 days of educational follow-up via WhatsApp®, and a control group receiving no additional training.

The primary goal is to assess changes in physicians' knowledge about inpatient glycemic control. Secondary goals include evaluating the quality of insulin prescriptions, rates of hyperglycemia and hypoglycemia, and hospital length of stay.

Read the detailed description

Hospital hyperglycemia is associated with increased morbidity, length of stay, and hospital costs, especially when not properly managed. Many internal medicine teams lack adequate training on glycemic control in hospitalized patients, and guidelines are not consistently followed in clinical practice.

This multicenter, randomized, open-label trial is designed to evaluate whether a telemedicine-based educational intervention can improve medical knowledge and clinical management of inpatient hyperglycemia. Internal medicine residents from four university hospitals in southern Brazil are randomized by clinical team into two groups: one receives a 30-minute online class and continued support via WhatsApp® for 30 days; the control group receives no intervention.

Medical knowledge is assessed using a validated questionnaire before and after the intervention. Secondary outcomes include the appropriateness of glycemic monitoring and insulin prescriptions, frequency of hyper- and hypoglycemia and hospital length of stay.

Being tested
Educational Intervention via Telemedicine
Keywords
diabetes mellitus, telemedicine, medical education, hospital hyperglycemia, insulin therapy
Medical subject headings
Diabetes Mellitus, Type 2, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Educational Intervention via TelemedicineBehavioural

    A structured educational program delivered remotely through WhatsApp®, including a 30-minute online lecture and daily dissemination of educational content (videos, texts, and practical guidance) on hospital hyperglycemia and glycemic management strategies.

Study groups in NCT07108426
Study groupRoleWhat they receive
Telemedicine Education GroupExperimentalInternal medicine residents in this group will receive a 30-minute online theoretical class on hospital hyperglycemia, taught by hospital-based endocrinologists. After the class, for 30 days, participants will be included in a continuing medical education group via the WhatsApp® application, where they will receive short educational videos and supporting materials related to diabetes and inpatient glycemic control.
Receives: Behavioral: Educational Intervention via Telemedicine
Routine Clinical Practice GroupNo interventionInternal medicine residents in this group will not receive any theoretical class or continuing education intervention. They will continue their standard clinical duties and usual care practices during the study period, without additional materials or support related to inpatient diabetes management.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in medical knowledge regarding inpatient hyperglycemia

    Medical knowledge will be assessed using a structured and validated questionnaire on hospital hyperglycemia and diabetes, administered before and 30 days after the intervention. The questionnaire includes multiple-choice clinical case scenarios related to glycemic monitoring, insulin use, treatment errors, and glycemic targets.

    Measured: Baseline and 30 days post-intervention

Secondary outcomes (6)

  1. Occurrence of hyperglycemia

    Percentage of capillary glucose (CG) readings >180 mg/dL during the last 5 days of hospitalization.

    Measured: Last 5 days of hospitalization during the 30-day intervention period

  2. Quality of insulin prescription

    Proportion of prescriptions that include appropriate insulin regimens (e.g., basal or basal-bolus) versus sliding-scale insulin alone.

    Measured: Last 5 days of hospitalization during the 30-day intervention period

  3. Occurrence of hypoglycemia

    Percentage of CG readings <70 mg/dL during the last 5 days of hospitalization.

    Measured: Last 5 days of hospitalization during the 30-day intervention period

  4. Time in glycemic target range

    Percentage of CG readings within the 70-180 mg/dL range during the last 5 days of hospitalization.

    Measured: Last 5 days of hospitalization during the 30-day intervention period

  5. Glycated hemoglobin ordered at hospital admission

    Proportion of patients for whom glycated hemoglobin (HbA1c) was ordered at admission.

    Measured: During the 30-day intervention period

  6. Length of hospital stay

    Duration in days from hospital admission to discharge.

    Measured: During the 30-day intervention period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2025
  2. Study start1 Aug 2024
  3. Primary completion31 May 2025
  4. Study completion31 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a multicenter, open-label, parallel-group randomized clinical trial designed to assess the impact of a structured medical education program on physicians' knowledge and hospital outcomes in patients with diabetes. Internal medicine resident teams from four Brazilian university hospitals were randomized to either an intervention group, which received a virtual class and 30-day follow-up via WhatsApp®, or a control group with usual practice. Outcomes include improvement in medical knowledge, quality of diabetes-related prescriptions, glycemic control, hospital length of stay, and readmission rates.
Masking
None (open label)
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07108426
Sponsor's protocol ID
84125324.4.1001.5335
Acronym
LELOHG
Status last verified
Aug 2025
First submitted
19 Jul 2025
Last updated
7 Aug 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared due to privacy concerns and lack of participant consent for external data sharing.

Publications

  • Lopes JDF, Andrade PDR, Borges MT, Krause MC, Simi MOS, Bohlke M, Weinert LS. Medical education on hospital hyperglycemia improving knowledge and outcomes. Arch Endocrinol Metab. 2024 Feb 19;68:e230003. doi: 10.20945/2359-4292-2023-0003. eCollection 2024.

    PubMed 39420910

  • Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, Manns BJ, Tonelli M; Alberta Kidney Disease Network. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ. 2017 Mar 6;189(9):E341-E364. doi: 10.1503/cmaj.150885. Epub 2016 Oct 31.

    PubMed 27799615

  • Mendez CE, Umpierrez GE. Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectr. 2014 Aug;27(3):180-8. doi: 10.2337/diaspect.27.3.180.

    PubMed 26246777

  • Umpierrez GE, Reyes D, Smiley D, Hermayer K, Khan A, Olson DE, Pasquel F, Jacobs S, Newton C, Peng L, Fonseca V. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care. 2014 Nov;37(11):2934-9. doi: 10.2337/dc14-0479. Epub 2014 Aug 28.

    PubMed 25168125

  • Horton WB, Law S, Darji M, Conaway MR, Akbashev MY, Kubiak NT, Kirby JL, Thigpen SC. A MULTICENTER STUDY EVALUATING PERCEPTIONS AND KNOWLEDGE OF INPATIENT GLYCEMIC CONTROL AMONG RESIDENT PHYSICIANS: ANALYZING THEMES TO INFORM AND IMPROVE CARE. Endocr Pract. 2019 Dec;25(12):1295-1303. doi: 10.4158/EP-2019-0299. Epub 2019 Aug 14.

    PubMed 31412227

  • Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization. Endocr Pract. 2012 Sep-Oct;18(5):651-9. doi: 10.4158/EP11314.OR.

    PubMed 22440990

  • Bansal V, Mottalib A, Pawar TK, Abbasakoor N, Chuang E, Chaudhry A, Sakr M, Gabbay RA, Hamdy O. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. BMJ Open Diabetes Res Care. 2018 Apr 5;6(1):e000460. doi: 10.1136/bmjdrc-2017-000460. eCollection 2018.

    PubMed 29657719

  • Rubin DJ. Hospital readmission of patients with diabetes. Curr Diab Rep. 2015 Apr;15(4):17. doi: 10.1007/s11892-015-0584-7.

    PubMed 25712258

  • Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009 Jun;32(6):1119-31. doi: 10.2337/dc09-9029. Epub 2009 May 8. No abstract available.

    PubMed 19429873

Questions about this trial

What is this clinical trial studying?

A study testing Educational Intervention via Telemedicine in people with Diabete Type 2 and Hyperglycemic Therapy, run by Catholic University of Pelotas at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in medical knowledge regarding inpatient hyperglycemia (time frame: Baseline and 30 days post-intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07108426, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in